<p>加拿大人寿保险公司在最近向证券交易委员会（SEC）披露的文件中表示，在第四季度将其在强生（NYSE:JNJ - 免费报告）的持仓降低了 15.5%。该基金在此期间出售了 515,770 股后，持有 2,816,343 股强生的股票。强生大约占加拿大人寿保险公司投资组合的 0.7%，是其第 20 大持股。截至最近一个季度末，加拿大人寿保险公司持有的强生股份约占 0.12%，价值 407,080,000 美元。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<ul>
<li>强生的收益好于坏——是时候买入了吗？</li>
</ul>
<p>其他一些大型投资者最近也买卖了该公司的股票。IFS Advisors LLC 在第四季度将其在强生的持仓增加了 138.9%。IFS Advisors LLC 现在拥有 172 股强生的股票，价值 25,000 美元，此前在此期间又购买了 100 股。WealthTrak Capital Management LLC 在第四季度购买了价值约 26,000 美元的强生新股份。Mountain Hill Investment Partners Corp.在第四季度购买了价值 29,000 美元的强生新股份。Bay Harbor Wealth Management LLC 在第四季度购买了价值约 32,000 美元的强生新股份。最后，Conquis Financial LLC 在第四季度购买了价值约 33,000 美元的强生新股份。对冲基金和其他机构投资者持有该公司 69.55% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位分析师最近对 JNJ 股票发表了评论。巴克莱将强生股票的目标价从 159.00 美元上调至 166.00 美元，并在 1 月 28 日的研究报告中给予该公司 “持平” 的评级。StockNews.com 在 1 月 25 日的研究报告中将强生的评级从 “买入” 上调至 “强力买入”。雷蒙德·詹姆斯在周一的报告中将强生的目标价从 165.00 美元下调至 162.00 美元，并对该公司设定了 “跑赢大盘” 的评级。Leerink Partners 在 1 月 23 日的报告中将强生股票的目标价从 182.00 美元下调至 169.00 美元，并对该股票设定了 “跑赢大盘” 的评级。最后，高盛在 4 月 9 日的报告中将强生的评级从 “中性” 上调至 “买入”，并将该公司的目标价从 157.00 美元上调至 172.00 美元。九位投资分析师对该股票给予了持有评级，九位给予了买入评级，两位给予了强力买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 171.78 美元。</p>
<ul>
<li>2 只低调的消费品股票，具有高股息</li>
</ul>
<p><strong>获取我们对强生的最新股票分析</strong></p>
<h2>强生的内部买卖</h2>
<p>在其他强生新闻中，执行副总裁 Timothy Schmid 在 2 月 18 日的交易中出售了 403 股该公司的股票。这些股票以 156.15 美元的平均价格出售，总交易额为 62,928.45 美元。出售完成后，该执行副总裁现在直接持有 15,098 股公司股票，价值 2,357,552.70 美元。这笔交易使其持股减少了 2.60%。该交易在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，副总裁 Robert J. Decker 在 2 月 25 日的交易中出售了 6,999 股该股票。这些股票以 165.88 美元的平均价格出售，总价值为 1,160,994.12 美元。出售完成后，该副总裁现在持有 21,001 股公司股票，价值约 3,483,645.88 美元。这代表其持股减少了 25.00%。该出售的披露信息可以在这里找到。0.16% 的股票由内部人士持有。</p>
<h2>强生股票上涨 0.2%</h2>
<ul>
<li>“质量” 轮换：回归基本投资</li>
</ul>
<p>强生股票在周四开盘价为 153.95 美元。该公司的 50 日移动平均线为 159.40 美元，200 日移动平均线为 155.10 美元。该股票的市值为 3710 亿美元，市盈率为 23.15，市盈增长比率为 2.56，贝塔值为 0.49。该公司的流动比率为 1.11，速动比率为 0.86，债务股本比率为 0.43。强生的 12 个月低点为 140.68 美元，12 个月高点为 169.99 美元。</p>
<p>强生（NYSE:JNJ - 获取免费报告）在 4 月 15 日最后发布了其收益结果。该公司报告本季度每股收益为 2.77 美元，超出分析师共识预期的 2.59 美元，超出 0.18 美元。该公司本季度的收入为 218.9 亿美元，而共识预期为 216.5 亿美元。强生的股本回报率为 34.24%，净利润率为 18.20%。研究分析师平均预计强生在当前财政年度将发布 10.58 美元的每股收益。</p>
<h2>强生增加股息</h2>
<p>该公司最近还披露了季度股息，将于 6 月 10 日支付。5 月 27 日的登记投资者将获得每股 1.30 美元的股息。这相当于年化 5.20 美元的股息，收益率为 3.38%。除息日期为 5 月 27 日。这比强生之前的季度股息 1.24 美元有所增加。强生的股息支付比率（DPR）目前为 74.59%。</p>
<h2>强生简介</h2>
<p>（免费报告）</p>
<p>强生是一家控股公司，专注于医疗保健领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比强生更好的股票</li>
<li>寻找并盈利交易 52 周低点的股票</li>
<li>摩根士丹利：3 只在波动中将蓬勃发展的金融股</li>
<li>10 美元以下的最佳股票</li>
<li>随着增长战略的多样化，Spotify 股票上涨</li>
<li>投资优先股与普通股的比较</li>
<li>维京治疗公司股票上涨但难以保持涨幅</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在强生吗？</h2>
<p>在你考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>加拿大人寿保险公司在第四季度减少了对强生（NYSE:JNJ）15.5% 的持股，目前持有 2,816,343 股，出售了 515,770 股。这大约占其投资组合的 0.7%，估值约为 4.07 亿美元。其他投资者也调整了他们的持仓，巴克莱将 JNJ 股票的目标价从 159 美元上调至 166 美元。分析师普遍将该股票评级为 “适度买入”，共识目标价为 171.78 美元</p>

<p>CANADA LIFE ASSURANCE Co lowered its position in Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 15.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,816,343 shares of the company's stock after selling 515,770 shares during the period. Johnson &amp; Johnson makes up approximately 0.7% of CANADA LIFE ASSURANCE Co's investment portfolio, making the stock its 20th biggest holding. CANADA LIFE ASSURANCE Co owned approximately 0.12% of Johnson &amp; Johnson worth $407,080,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>加拿大人寿保险公司在最近向证券交易委员会（SEC）披露的文件中表示，在第四季度将其在强生（NYSE:JNJ - 免费报告）的持仓降低了 15.5%。该基金在此期间出售了 515,770 股后，持有 2,816,343 股强生的股票。强生大约占加拿大人寿保险公司投资组合的 0.7%，是其第 20 大持股。截至最近一个季度末，加拿大人寿保险公司持有的强生股份约占 0.12%，价值 407,080,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><ul>
<li>Johnson &amp; Johnson Earnings Were More Good Than Bad—Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>强生的收益好于坏——是时候买入了吗？</li>
</ul>
</div><p>A number of other large investors also recently bought and sold shares of the business. IFS Advisors LLC increased its position in Johnson &amp; Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after purchasing an additional 100 shares during the period. WealthTrak Capital Management LLC bought a new position in Johnson &amp; Johnson in the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new position in shares of Johnson &amp; Johnson in the 4th quarter valued at $29,000. Bay Harbor Wealth Management LLC bought a new position in Johnson &amp; Johnson in the fourth quarter worth about $32,000. Finally, Conquis Financial LLC purchased a new stake in Johnson &amp; Johnson during the fourth quarter valued at approximately $33,000. Hedge funds and other institutional investors own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>其他一些大型投资者最近也买卖了该公司的股票。IFS Advisors LLC 在第四季度将其在强生的持仓增加了 138.9%。IFS Advisors LLC 现在拥有 172 股强生的股票，价值 25,000 美元，此前在此期间又购买了 100 股。WealthTrak Capital Management LLC 在第四季度购买了价值约 26,000 美元的强生新股份。Mountain Hill Investment Partners Corp.在第四季度购买了价值 29,000 美元的强生新股份。Bay Harbor Wealth Management LLC 在第四季度购买了价值约 32,000 美元的强生新股份。最后，Conquis Financial LLC 在第四季度购买了价值约 33,000 美元的强生新股份。对冲基金和其他机构投资者持有该公司 69.55% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several analysts recently commented on JNJ shares. Barclays raised their price target on shares of Johnson &amp; Johnson from $159.00 to $166.00 and gave the company an &#34;equal weight&#34; rating in a research report on Tuesday, January 28th. StockNews.com raised Johnson &amp; Johnson from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, January 25th. Raymond James lowered their price target on Johnson &amp; Johnson from $165.00 to $162.00 and set an &#34;outperform&#34; rating for the company in a report on Monday. Leerink Partners cut their price objective on shares of Johnson &amp; Johnson from $182.00 to $169.00 and set an &#34;outperform&#34; rating on the stock in a report on Thursday, January 23rd. Finally, The Goldman Sachs Group upgraded shares of Johnson &amp; Johnson from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and upped their target price for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Nine investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $171.78.</p>
<div class="lb-trans"><p>几位分析师最近对 JNJ 股票发表了评论。巴克莱将强生股票的目标价从 159.00 美元上调至 166.00 美元，并在 1 月 28 日的研究报告中给予该公司 “持平” 的评级。StockNews.com 在 1 月 25 日的研究报告中将强生的评级从 “买入” 上调至 “强力买入”。雷蒙德·詹姆斯在周一的报告中将强生的目标价从 165.00 美元下调至 162.00 美元，并对该公司设定了 “跑赢大盘” 的评级。Leerink Partners 在 1 月 23 日的报告中将强生股票的目标价从 182.00 美元下调至 169.00 美元，并对该股票设定了 “跑赢大盘” 的评级。最后，高盛在 4 月 9 日的报告中将强生的评级从 “中性” 上调至 “买入”，并将该公司的目标价从 157.00 美元上调至 172.00 美元。九位投资分析师对该股票给予了持有评级，九位给予了买入评级，两位给予了强力买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 171.78 美元。</p>
</div><ul>
<li>2 Under-the-Radar Consumer Staples Stocks With Big Dividends</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只低调的消费品股票，具有高股息</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on Johnson &amp; Johnson</strong></p>
<div class="lb-trans"><p><strong>获取我们对强生的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling at Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>强生的内部买卖</h2>
</div><p>In other Johnson &amp; Johnson news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他强生新闻中，执行副总裁 Timothy Schmid 在 2 月 18 日的交易中出售了 403 股该公司的股票。这些股票以 156.15 美元的平均价格出售，总交易额为 62,928.45 美元。出售完成后，该执行副总裁现在直接持有 15,098 股公司股票，价值 2,357,552.70 美元。这笔交易使其持股减少了 2.60%。该交易在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，副总裁 Robert J. Decker 在 2 月 25 日的交易中出售了 6,999 股该股票。这些股票以 165.88 美元的平均价格出售，总价值为 1,160,994.12 美元。出售完成后，该副总裁现在持有 21,001 股公司股票，价值约 3,483,645.88 美元。这代表其持股减少了 25.00%。该出售的披露信息可以在这里找到。0.16% 的股票由内部人士持有。</p>
</div><h2>Johnson &amp; Johnson Trading Up 0.2 %</h2>
<div class="lb-trans"><h2>强生股票上涨 0.2%</h2>
</div><ul>
<li>The &#34;Quality&#34; Rotation: Back to Basics Investing</li>
</ul>
<div class="lb-trans"><ul>
<li>“质量” 轮换：回归基本投资</li>
</ul>
</div><p>Shares of Johnson &amp; Johnson stock opened at $153.95 on Thursday. The company has a 50-day moving average of $159.40 and a two-hundred day moving average of $155.10. The stock has a market cap of $371.00 billion, a PE ratio of 23.15, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson &amp; Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.</p>
<div class="lb-trans"><p>强生股票在周四开盘价为 153.95 美元。该公司的 50 日移动平均线为 159.40 美元，200 日移动平均线为 155.10 美元。该股票的市值为 3710 亿美元，市盈率为 23.15，市盈增长比率为 2.56，贝塔值为 0.49。该公司的流动比率为 1.11，速动比率为 0.86，债务股本比率为 0.43。强生的 12 个月低点为 140.68 美元，12 个月高点为 169.99 美元。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson &amp; Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, research analysts anticipate that Johnson &amp; Johnson will post 10.58 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）在 4 月 15 日最后发布了其收益结果。该公司报告本季度每股收益为 2.77 美元，超出分析师共识预期的 2.59 美元，超出 0.18 美元。该公司本季度的收入为 218.9 亿美元，而共识预期为 216.5 亿美元。强生的股本回报率为 34.24%，净利润率为 18.20%。研究分析师平均预计强生在当前财政年度将发布 10.58 美元的每股收益。</p>
</div><h2>Johnson &amp; Johnson Increases Dividend</h2>
<div class="lb-trans"><h2>强生增加股息</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date is Tuesday, May 27th. This is a boost from Johnson &amp; Johnson's previous quarterly dividend of $1.24. Johnson &amp; Johnson's dividend payout ratio (DPR) is currently 74.59%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，将于 6 月 10 日支付。5 月 27 日的登记投资者将获得每股 1.30 美元的股息。这相当于年化 5.20 美元的股息，收益率为 3.38%。除息日期为 5 月 27 日。这比强生之前的季度股息 1.24 美元有所增加。强生的股息支付比率（DPR）目前为 74.59%。</p>
</div><h2>Johnson &amp; Johnson Profile</h2>
<div class="lb-trans"><h2>强生简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗保健领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Find and Profitably Trade Stocks at 52-Week Lows</li>
<li>Morgan Stanley: 3 Financial Stocks That Will Thrive in Volatility</li>
<li>Best Stocks Under $10.00</li>
<li>Spotify Stock Climbs as Its Growth Strategy Diversifies</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比强生更好的股票</li>
<li>寻找并盈利交易 52 周低点的股票</li>
<li>摩根士丹利：3 只在波动中将蓬勃发展的金融股</li>
<li>10 美元以下的最佳股票</li>
<li>随着增长战略的多样化，Spotify 股票上涨</li>
<li>投资优先股与普通股的比较</li>
<li>维京治疗公司股票上涨但难以保持涨幅</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

加拿大人寿保险公司减少了其在强生公司（NYSE:JNJ）的持仓